Lets hope that this works for the patients that will be participating in the Oasis trials. Its almost been 4 years since the team at the City of Hope their research announced to the world of how they can use an oncolytic vaccinia virus know back then as OV19t to express a CD19t (CF33-CD19t) in solid tumors potentially opening up the cancer cells for targeting by CAR-T therapy.
I'm just going back to look into this again and I find it amazing that there hasn't been more coverage on this. For our sake, I hope Imugene is saving it for the expected positive outcome, otherwise... lets not go there yet, I think the market, to some degree, has already priced some of that in already.
"The holy grail of a cancer therapy is its universality is to apply one type of therapy irrespective of the origins of that cancer that would be the holy grail you don's have to redefine your therapy depending on that patient and their specific cancer and that is what we hope to achieve with this. My name is Saul Priceman..."
GLTA, we will know soon enough. Whats a few months, its already been 3 years since Imugene acquired the license. "Drug development is not for the faint of heart..." Leslie Chong
IMU Price at posting:
5.7¢ Sentiment: Hold Disclosure: Held
